VIVS (Organovo Holdings, Inc.) רווחיות לפי רווח גולמי

סמל תאגידי ולוגו של Organovo Holdings (VIVS)

VivoSim Labs Inc (VIVS) consistently operates its tissue bioprinting capacities, eliminating equipment downtime. Business efficiency is based on the precision of 3D models during drug testing, as confirmed by the GURU.Markets terminal linear chart for gross margin as a percentage of revenue, where the indicator reached -67.40. The development strategy relies on creating organs for transplantation, reducing research costs for pharma behemoths.

רווחיות גולמית organovo.com (VIVS): לתקופה 25.04.2025 - 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Organovo (VIVS)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
- מדדי הערכת שווי שוק של העסק:
ניתוח בסיסי של החברה:VIVS (Organovo Holdings)
מוצרים מיוצרים של organovo.com

To select fundamentally strong assets, it is essential for an investor to evaluate production efficiency through operating profitability. Gross margin measures the portion of revenue remaining after deducting direct product creation costs, reflecting the business's pricing power. For VivoSim Labs Inc (VIVS), with its unique bioprinting patents, this metric confirms the high value of its technologies, as clearly demonstrated by the gross profit margin.